Arcellx, Inc.
NASDAQ:ACLX
67.72 (USD) • At close February 4, 2025
Overzicht | Financiële gegevens
Bedrijfsnaam | Arcellx, Inc. |
Symbool | ACLX |
Munteenheid | USD |
Prijs | 67.72 |
Beurswaarde | 3,661,936,652 |
Dividendpercentage | 0% |
52-weken bereik | 47.88 - 107.37 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Rami Elghandour |
Website | https://arcellx.com |
An error occurred while fetching data.
Over Arcellx, Inc.
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)